Aledort L - Search Results

1

Convalescent plasma for administration of passive antibodies against viral agents.

Di Minno G, Mannucci PM, Ironside JW, Perno CF, Gürtler L, Aledort L. Di Minno G, et al. Among authors: aledort l. Haematologica. 2020 Dec 1;105(12):2710-2715. doi: 10.3324/haematol.2020.267427. Haematologica. 2020. PMID: 33256373 Free PMC article. No abstract available.

2

Factor VIII replacement is still the standard of care in haemophilia A.

Aledort L, Mannucci PM, Schramm W, Tarantino M. Aledort L, et al. Blood Transfus. 2019 Nov;17(6):479-486. doi: 10.2450/2019.0211-19. Epub 2019 Dec 11. Blood Transfus. 2019. PMID: 31846611 Free PMC article. Review.

3

Are all licensed haemostatic agents for haemophilia therapy accessible to patients?

Berger K, Batorova A, Bohn R, di Minno M, Mannucci PM, Kavakli K, Schramm W, Aledort L; International Prophylaxis Study Group. Berger K, et al. Among authors: aledort l. Haemophilia. 2022 Nov;28(6):e256-e258. doi: 10.1111/hae.14660. Epub 2022 Sep 19. Haemophilia. 2022. PMID: 36122901 No abstract available.

4

Low risk of viral infection after administration of vapor-heated factor VIII concentrate. International Investigator Group.

Mannucci PM, Schimpf K, Abe T, Aledort LM, Anderle K, Brettler DB, Hilgartner MW, Kernoff PB, Kunschak M, McMillan CW, et al. Mannucci PM, et al. Among authors: aledort lm. Transfusion. 1992 Feb;32(2):134-8. doi: 10.1046/j.1537-2995.1992.32292180141.x. Transfusion. 1992. PMID: 1311876 Clinical Trial.

5

Immune status of human immunodeficiency virus seropositive and seronegative hemophiliacs infused for 3.5 years with recombinant factor VIII. The Kogenate Study Group.

Mannucci PM, Brettler DB, Aledort LM, Lusher JM, Abildgaard CF, Schwartz RS, Hurst D. Mannucci PM, et al. Among authors: aledort lm. Blood. 1994 Apr 1;83(7):1958-62. Blood. 1994. PMID: 7908234 Free article.

6

Fifth Åland Island conference on von Willebrand disease.

Berntorp E, Ågren A, Aledort L, Blombäck M, Cnossen MH, Croteau SE, von Depka M, Federici AB, Goodeve A, Goudemand J, Mannucci PM, Mourik M, Önundarson PT, Rodeghiero F, Szántó T, Windyga J. Berntorp E, et al. Among authors: aledort l. Haemophilia. 2018 May;24 Suppl 4:5-19. doi: 10.1111/hae.13475. Haemophilia. 2018. PMID: 29687935 Free article.

7

Hemophilia treatment. Immune tolerance induction: treatment duration analysis and economic considerations.

Aledort LM, Kroner B, Mariani G. Aledort LM, et al. Haematologica. 2000 Oct;85(10 Suppl):83-5. Haematologica. 2000. PMID: 11187881 No abstract available.

8

Safety of human plasma-derived clotting factor products and their role in haemostasis in patients with haemophilia: meeting report.

Tarantino M, Ma A, Aledort L. Tarantino M, et al. Among authors: aledort l. Haemophilia. 2007 Sep;13(5):663-9. doi: 10.1111/j.1365-2516.2007.01481.x. Haemophilia. 2007. PMID: 17880460 No abstract available.

9

Advances in clotting factor treatment for congenital hemorrhagic disorders.

Tarantino MD, Aledort LM. Tarantino MD, et al. Clin Adv Hematol Oncol. 2004 Jun;2(6):363-8. Clin Adv Hematol Oncol. 2004. PMID: 16163206 Review.

10

Circumcision and haemophilia: a perspective.

Kavakli K, Aledort LM. Kavakli K, et al. Among authors: aledort lm. Haemophilia. 1998 Jan;4(1):1-3. doi: 10.1046/j.1365-2516.1998.00155.x. Haemophilia. 1998. PMID: 9873857 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

330 results

Search Page

Filters